Consequences of hypoxia-reoxygenation phenomena in patients with obstructive sleep apnea syndrome.
OBJECTIVE
Obstructive sleep apnea syndrome (OSAS) is a common disorder characterized by numerous episodes of absence of respiratory flow during sleep, which can be followed by a decrease in SaO2, which is rapidly normalized when ventilation resumes. We hypothesize that this hypoxia-reoxygenation phenomena may affect the generation of vascular endothelial growth factor (VEGF), erythropoietin (EPO), endothelin-1 (ENDO-1), and inducible nitric oxide synthase (iNOS).


METHODS
Prospective, patients referred to sleep disorders center.


METHODS
The presence and severity of OSAS were determined using the standard overnight polysomnography. Diagnosis of OSAS was made when the apnea-hypopnea index (AHI) was ≥15, independent of the appearance of symptoms. Serum levels of VEGF, EPO, ENDO-1, and nitrite-nitrate were measured after overnight fasting in 69 patients with OSAS and in 17 healthy control subjects. Serum levels of VEGF and nitrite-nitrate were measured again after 12 weeks of treatment with continuous positive airway pressure (CPAP) in OSAS patients.


RESULTS
Serum VEGF levels were found to be significantly higher and nitrite-nitrate levels were found to be significantly lower in OSAS patients than in controls (P=.003, .008, respectively), but no differences in EPO and ENDO-1 levels were found between the groups. We demonstrated that in OSAS patients, the serum VEGF levels were decreased and nitrate levels were increased after 12 weeks of CPAP treatment (P=.001, .002, respectively).


CONCLUSIONS
According to our data, it is likely that hypoxia-reoxygenation phenomena affect the VEGF and nitrite-nitrate levels, which may be pathogenic factors in generating cardiovascular complications in OSAS.
Sleep Disorders Center, Gazi University Faculty of Medicine, Ankara, Turkey.
Tansu Ulukavak
TU
Ciftci
Oguz
O
Kokturk
Senay
S
Demirtas
Ozlem
O
Gulbahar
Neslihan
N
Bukan
D000328:Adult; D045422:Continuous Positive Airway Pressure; D019332:Endothelin-1 / Q000097:blood; D004921:Erythropoietin / Q000097:blood; D005260:Female; D005609:Free Radicals; D006801:Humans; D000860:Hypoxia / Q000097:blood* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009566:Nitrates / Q000097:blood*; D052247:Nitric Oxide Synthase Type II / Q000097:blood; D009573:Nitrites / Q000097:blood*; D010100:Oxygen / Q000097:blood*; D017286:Polysomnography; D011446:Prospective Studies; D020181:Sleep Apnea, Obstructive / Q000097:blood* / Q000503:physiopathology / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D019332:Endothelin-1; D005609:Free Radicals; D009566:Nitrates; D009573:Nitrites; D042461:Vascular Endothelial Growth Factor A; D004921:Erythropoietin; D052247:Nitric Oxide Synthase Type II; D010100:Oxygen
FASEB J. 1999 Jan;13(1):9-22
9872925
Am J Hypertens. 2004 Sep;17(9):783-6
15363820
Am J Respir Crit Care Med. 2000 Dec;162(6):2166-71
11112132
Cardiology. 2009;112(1):62-8
18580062
Prog Cardiovasc Dis. 1995 Sep-Oct;38(2):105-28
7568902
Circulation. 2005 Oct 25;112(17):2660-7
16246965
Intern Med. 2003 Aug;42(8):681-5
12924491
Circ J. 2005 Feb;69(2):221-6
15671617
Sleep. 1999 Aug 1;22(5):667-89
10450601
Scand J Clin Lab Invest. 1996 Nov;56(7):577-81
8981652
Arch Intern Med. 2005 Nov 14;165(20):2408-13
16287771
Chest. 1990 Jan;97(1):27-32
2295260
Prog Cardiovasc Dis. 1995 Sep-Oct;38(2):87-104
7568906
N Engl J Med. 1993 Apr 29;328(17):1230-5
8464434
Chest. 2005 Jun;127(6):2076-84
15947323
Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282(6):L1314-23
12003788
Thorax. 1997 Oct;52(10):872-8
9404374
Am J Hypertens. 2007 Jan;20(1):44-52
17198911
Int J Cardiol. 1991 Sep;32(3):347-51
1791087
Acta Physiol Scand. 1992 Jul;145(3):201-27
1381545
Chest. 2001 May;119(5):1401-8
11348945
Clin Chem. 1997 Jan;43(1):64-70
8990224
J Appl Physiol (1985). 2005 Nov;99(5):1998-2007
16227461
Sleep. 1992 Apr;15(2):173-84
11032543
J Sleep Res. 2007 Jun;16(2):217-25
17542952
Sleep Med Rev. 2005 Jun;9(3):211-24
15893251
Sleep. 2002 Feb 1;25(1):59-65
11833862